Georgetown Univ, KYAN Therapeutics to Drive AI-based Cancer Research
KYAN Therapeutics, Inc. (“KYAN”), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for...
